Web Research
Web Research — What the Internet Knows
The Bottom Line from the Web
2026 is a year of forced strategic reinvention. The Feb 4, 2026 FTC consent order is restructuring PBM economics with no fine but sweeping operational mandates; the Bernstein Litowitz racketeering class action filed weeks later contests the rebate-and-pass-through accounting underpinning Evernorth profits. Against that overhang, Cigna beat Q1 2026 ($7.79 adj EPS, +16% YoY), raised FY26 guide to ≥$30.35, and Street targets reset into a $305–$371 range ahead of the July 1 CEO transition from David Cordani to Brian Evanko.
What Matters Most
1. FTC consent order on Express Scripts is the most consequential PBM overhaul to date
On Feb 4, 2026 the FTC secured a landmark consent order with Express Scripts requiring "fundamental changes to its business practices" — increased transparency, restrictions on rebate-driven insulin pricing, and an estimated $7B / 10-year out-of-pocket relief for patients plus new revenue routed to community pharmacies. CI's 10-K frames the settlement as carrying "no monetary penalty, finding of fault, or admission of liability" — but Bloomberg Law calls it "the most consequential structural overhaul of the PBM industry to date." Sources: ftc.gov, bloomberglaw.com, sec.gov/CI 10-K.
The contradiction matters: the filing-side framing ("no penalty, no fault") understates the operational and margin impact. Express Scripts must overhaul rebate practices and adopt insulin-affordability remedies — costs that flow through Evernorth's Pharmacy Benefit Services (PBS) line, which already saw pre-tax adjusted earnings drop 28% to $394M in Q1 2026.
2. Bernstein Litowitz racketeering class action — Ascent Health Services rebate diversion
In February 2026, Bernstein Litowitz Berger & Grossmann LLP filed a class-action alleging that Express Scripts, Cigna, and Evernorth diverted billions in drug rebates from PBM clients to an offshore Swiss vehicle called Ascent Health Services through allegedly improper pass-through arrangements — framed as a RICO/racketeering case. This is materially incremental to the FTC matter and tests the related-party accounting that underpins Evernorth rebate revenue. Sources: finance.yahoo.com, healthcareuncovered.substack.com.
If the case survives motions, expanded related-party disclosure on Ascent — the Swiss group purchasing organization Cigna shares with other PBMs — could rebase reported PBS economics.
3. PxDx automated-denial class action advanced past motion to dismiss
On March 31, 2025 a federal judge advanced class claims against Cigna over its PxDx algorithm, which a 2023 ProPublica investigation found let Cigna doctors spend an average of 1.2 seconds per claim review before denial. Breach-of-fiduciary-duty and unfair-competition counts survived. This is the single largest governance/regulatory tail risk and reaches the board's clinical-oversight credibility. Sources: courthousenews.com, employmentlawweekly.com, propublica.org (cited in Reddit r/Futurology thread).
4. CEO transition: Brian Evanko succeeds David Cordani July 1, 2026
Cigna confirmed on March 3, 2026 that President & COO Brian Evanko will become CEO effective July 1, 2026; Cordani transitions to Executive Chair. Evanko is positioning the company around "consumer-focused, AI-enabled health services and care for clinically complex patients." The succession is internal and orderly, but the new CEO inherits FTC compliance milestones, the PxDx litigation, Signature-model rollout, and the eviCore review on Day One. Sources: prnewswire.com, healthcaredive.com, marketscreener.com.
5. Q1 2026 beat + raised FY26 guidance — Street targets reset
Q1 2026 revenue $68.5B, adjusted EPS $7.79 (+16% YoY, beat consensus by 2.4%). Management raised FY26 adjusted EPS guidance to at least $30.35 (from ~$30.25). Cigna Healthcare MCR came in at 79.8% — well below the FY26 guide range of 83.7–84.7%. Sources: stocktitan.net, fool.com, marketbeat.com.
6. Portfolio reshaping — ACA exit by end-2026 and eviCore strategic review
Management committed on the Q1 2026 call to exit the individual ACA exchange business by year-end 2026 and to launch a strategic review of eviCore (utilization-management platform inside Evernorth). Both moves reduce volatility but introduce mix and capital-deployment uncertainty. Sources: wsj.com, benefitspro.com, marketbeat.com.
7. Signature rebate-free PBM model — 30% lower brand pricing, 50% adoption target by 2028
Evernorth's "Signature" model (announced Oct 27, 2025) targets ~30% lower brand drug pricing with full transparency. Management is guiding to ≥50% of Evernorth PBS members on Signature by year-end 2028. Retention through the transition is reportedly mid-90s, with Evanko citing "over 97% retention" exiting 2026. Sources: evernorth.com, marketbeat.com.
8. HHS-OIG Corporate Integrity Agreement remains active through Sept 2028
The 2023 $172M False Claims Act settlement (Medicare Advantage chart-review/risk-adjustment practices) carries an active Corporate Integrity Agreement through September 2028 with a $135.3M reportable settlement amount. Reportable events under the CIA can be FCA traps; legal commentators flag CIA-period FCA exposure as a recurring enforcement risk. Sources: oig.hhs.gov, phillipsandcohen.com, arnoldporter.com.
9. Q4 2024 stop-loss miss — overhang on commercial credibility
The Q4 2024 stop-loss miss (large-claim severity in the self-insured employer book) drove FY24 MCR to 83.2%, above guidance, and prompted public commitments to "corrective actions." External commentary framed it as a window into how sick American workers are; Cigna has not disclosed root cause (underwriting drift vs. severity vs. mix). Q1 2026 MCR of 79.8% reads as evidence the corrective actions are working. Sources: statnews.com, finance.yahoo.com.
10. VillageMD writedown — capital-allocation scar tissue
In May 2024 Cigna recognized a ~$300M loss on its VillageMD minority stake after Walgreens cut VillageMD's clinical footprint. Evernorth has since redeployed into specialty pharmacy ($3.5B ex-Walgreens specialty asset purchase). The episode is a reminder that minority-stake primary-care bets carry disproportionate write-down risk relative to disclosed earnings. Sources: healthcaredive.com, forbes.com.
Recent News Timeline
What the Specialists Asked
Governance and People Signals
Brian Evanko (CEO-elect, effective July 1, 2026). Internal succession from President & COO. Pay package not yet filed; Cigna's compensation architecture remains 92% performance-based with 77% in long-term equity. Source: panabee.com, salary.com.
David Cordani (CEO, transitioning to Executive Chair). 16+ year CEO tenure. Total compensation reported at ~$22.87M (7% salary / 93% bonus + equity), with direct ownership of 0.24% of CI (~$182.6M at recent prices). Executive-Chair structure (vs. non-executive Chair) is occasionally flagged by ISS/Glass Lewis. Source: simplywall.st, tradingview.com.
Active Corporate Integrity Agreement. Five-year CIA with HHS-OIG running through September 2028, tied to the September 2023 $172M False Claims Act settlement on Medicare Advantage chart-review/risk-adjustment practices ($135.3M reportable settlement). Source: oig.hhs.gov, phillipsandcohen.com.
Open litigation overhang:
- PxDx automated-denial class action — fiduciary-duty / unfair-competition claims advanced past motion to dismiss (March 31, 2025). Source: courthousenews.com.
- Bernstein Litowitz / Ascent Health Services class action — RICO/racketeering theory filed February 2026 alleging rebate diversion through Swiss vehicle. Source: finance.yahoo.com.
- Martella's Pharmacy class action (filed August 2025) — patients cut off from regional pharmacy network as part of broader pharmacy-network dispute. Source: tribdem.com (via wtaj.com).
Industry Context
Managed-care peer pressure (early 2026). Late-January 2026 saw managed-care stocks broadly sell off after a near-flat Medicare Advantage rate proposal — but Cigna outperformed peers because of its March 2025 HCSC sale, which materially reduced MA exposure. Beta of 0.31 (5Y monthly) marks Cigna as defensive within the group. Source: morningstar.com.
PBM regulatory environment. The Feb 4, 2026 FTC consent order against Express Scripts is described by Bloomberg Law as "the most consequential structural overhaul of the PBM industry to date." OptumRx (UNH) and CVS Caremark face parallel pressure. Cigna's preemptive Signature model launch (Oct 27, 2025) positions it as the first scaled PBM to volunteer transparency. Source: bloomberglaw.com, evernorth.com.
Vertical integration is consolidating to three integrated PBM-payer-pharmacy platforms. Following the 2018 Cigna-Express Scripts approval and CVS-Aetna combination, all three largest PBMs are tied to health plans (UNH/OptumRx, CVS/Caremark, CI/Express Scripts). CarelonRx (Elevance) is migrating in-house — secular share-loss risk for non-integrated PBMs. Source: hallrender.com.
ACA exchange volatility. Cigna's exit from individual ACA exchanges by end-2026 is a deliberate move out of a volatile retail segment. With enhanced subsidy renewal uncertain in Congress, peers face binary cliff risk in 2027; Cigna sidesteps it. Source: wsj.com.
GLP-1 spend intensity. Industry coverage flags GLP-1 cost intensity as a key driver of medical-cost trend; Specialty & Care Services growth (+20% YoY pre-tax in Q1 2026) reflects partial GLP-1 spend capture. Cigna does not disclose member-level GLP-1 spend.
Note. External evidence base for this section: 207 specialist-defined queries, 905 page texts read, plus the Parallel external dossier with cited findings. Page-level dollar figures are reported in USD as filed; quarterly/annual KPIs match company press releases.